Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections
about
Optimizing Polymyxin Combinations Against Resistant Gram-Negative BacteriaAntimicrobial Activity and Toxicity of the Major Lipopeptide Components of Polymyxin B and Colistin: Last-line Antibiotics against Multidrug-Resistant Gram-negative BacteriaMortality markers in nosocomial Klebsiella pneumoniae bloodstream infection.Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use.To B or not to B, that is the question: is it time to replace colistin with polymyxin B?Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria.Effectiveness and Safety of Tigecycline Compared with Other Broad-Spectrum Antimicrobials in Abdominal Solid Organ Transplant Recipients with Polymicrobial Intraabdominal Infections.Resurgence of Polymyxin B for MDR/XDR Gram-Negative Infections: An Overview of Current Evidence.Endotoxin neutralization by an O-antigen specific monoclonal antibody: A potential novel therapeutic approach against Klebsiella pneumoniae ST258.Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study.Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae in cancer patients.Efficacy and safety of low-dose colistin in the treatment for infections caused by multidrug-resistant gram-negative bacteria.Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy.
P2860
Q36363261-9065DD77-45B8-4A71-AFD0-878C719BFBF4Q37165591-755872CC-EDAD-43DE-BF56-0ED1BBD5F8D9Q37374197-37FF7876-1579-485A-B3ED-3256689B783DQ37562099-1DA839A3-FFFB-4053-BABA-4D6ACDF2110AQ38262873-F281C7AB-9D16-4D49-83F8-3B4F18BCF332Q38384662-39CD3CCF-72E3-43BC-86D4-8DBA3378B415Q39094941-80060514-325C-42BE-BD53-06462843C74BQ40111993-046652B1-9058-4424-A3F5-5F04A83770A1Q40365674-5B8394D1-74F7-4892-81C7-DC9C0E864B12Q41299450-315264F7-3951-4FA8-AEF8-C8BB34C7EE15Q42199910-B625FA28-F945-43E9-9C83-D3A1004B3F17Q44160090-A9AAA438-E8A7-4A87-BDE0-2006BE22D4C9Q44181170-AB08497D-845F-4440-A9D4-6BEFA38D72A5
P2860
Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Risk factors for treatment fai ...... ebsiella pneumoniae infections
@en
Risk factors for treatment fai ...... bsiella pneumoniae infections.
@nl
type
label
Risk factors for treatment fai ...... ebsiella pneumoniae infections
@en
Risk factors for treatment fai ...... bsiella pneumoniae infections.
@nl
prefLabel
Risk factors for treatment fai ...... ebsiella pneumoniae infections
@en
Risk factors for treatment fai ...... bsiella pneumoniae infections.
@nl
P2093
P2860
P356
P1476
Risk factors for treatment fai ...... ebsiella pneumoniae infections
@en
P2093
Diana Esaian
John Papadopoulos
Marco R Scipione
Sapna A Mehta
Ting-Yi Chen
Yanina Dubrovskaya
P2860
P304
P356
10.1128/AAC.00510-13
P407
P577
2013-08-19T00:00:00Z